Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dry swabs could simplify HPV screening

NCT ID NCT06213051

Diagnosis Sponsor: Foundation for Innovative New Diagnostics, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers compare two ways to collect vaginal samples for high-risk HPV testing: swabs stored dry and swabs stored in liquid. The study enrolls 1,306 women aged 30 and older who have abnormal cervical screening results. The goal is to see if dry swabs detect HPV as accurately as wet swabs, which could make screening easier in places without lab equipment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
self-collected vaginal swabs transported dry versus wet
What this could lead to
If dry swabs work as well as wet swabs, HPV screening could become simpler and cheaper, making it easier to reach women in areas without labs or refrigeration.
What could go wrong
Dry swabs might not preserve HPV DNA well enough, leading to missed infections. The study only includes women with abnormal screening results, so results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,306 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are eligible to be included in the study only if all of the inclusion criteria and none of the exclusion criteria indicated below apply. Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as protocol waivers or exemptions, are not permitted.

Ages

30 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria for participants screened and enrolled consecutively as they present at the clinical study site: * Sexually active adult females ≥30 years of age (≥25 years of age if HIV+) presenting for treatment at a facility with an abnormal cervical cancer screening result (abnormal cytology, visual inspection with acetic acid and/or colposcopy) * Able to understand scope of study * Able to provide written informed consent * Willing to provide all necessary samples Exclusion Criteria: * Vaccinated for HPV * Pregnancy * Patient not willing or unable to provide the all three swab samples (self-collected dry and wet and HCW collected cervical swabs)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papillomavirus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papillomavirus infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kenya Medical Research Institute (KEMRI)

    Nairobi, Nairobi County, 00100, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.